Becton Dickinson and Co (BDX) shares are trading lower after the FDA established a Digital Health Advisory Committee. The committee is dedicated to tackling challenges within the realm of digital health technologies, including AI, augmented reality, and wearable devices. The increased regulation could slow down the pace of innovation or make it more challenging for companies to bring new digital health products to market, which could negatively affect companies like BDX.